Research programme: allogeneic type 1 regulatory T cell therapies - Tr1X
Alternative Names: Research programme: allogeneic regulatory T (Treg) T cell therapies - Tr1XLatest Information Update: 26 Feb 2024
At a glance
- Originator Tr1X
- Class Gene therapies; Regulatory T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation